Clinical Trial

Study of Role of Blood Microvescicles and Exosomes in Patients With Graft Occlusion After Aortocoronary Bypass Surgery

Study acronym: MVBYPASS
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 28, 2024 (before its estimated June 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Coronary artery bypass graft (CABG) surgery is still the standard treatment of coronary revascularization for patients with severe coronary artery disease (CAD). Graft patency, together with completeness of revascularization, is a major determinant of long-term outcome following CABG. The surgical procedure elicits a persistent systemic inflammatory response associated with the activation of the hemostatic system leading to perturbation of endothelial and vascular function and activation of platelets and leukocytes. All of these events are the main players responsible for the early and late graft failure in a significant percentage of patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-06-06; most recent amendment 2024-08-27.
Trial Details
NCT Number NCT05411445
Lead Sponsor Maria Cecilia Hospital
Conditions Coronary Artery Bypass Surgery
Enrollment 300 participants
Start Date 2022-06-01
Primary Completion 2025-06-01 (estimated)
Study Completion 2025-09-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-28